Observational studyBMC pediatrics2026
Genotypic and phenotypic features of 23 Egyptian patients with tuberous sclerosis complex.
Observational study in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberous sclerosis complex (TSC) is a multisystem disease caused by pathogenic variants in TSC1 or TSC2 genes. Although features of TSC have been described in various populations, genetic data from Egypt remain scarce. This study aimed to characterize the phenotypic and molecular features of TSC among a cohort of Egyptian patients.
methodsThis observational study included patients clinically diagnosed with TSC at two Egyptian centers between 2022 and 2025. All participants underwent a comprehensive evaluation, including demographic profiling, clinical assessment, imaging studies, and whole-exome sequencing. Identified TSC1 and TSC2 variants were cross-referenced with public databases, analyzed using bioinformatics tools, and classified according to the American College of Medical Genetics and Genomics guidelines.
resultsThe cohort contained 23 cases from 20 unrelated families (16 males and 7 females; median age: 8.1 years). Parental consanguinity and positive family history were present in 13 and 12 cases, respectively. The median age at initial presentation was 8 months (interquartile range: 3-24 months). Patients exhibited various manifestations, including hypomelanotic macules (100%), cortical tubers (96%), seizures (87%), TSC-associated neuropsychiatric disorders (78%), facial angiofibromas (65%), shagreen patches (48%), renal angiomyolipomas (44%), and cardiac rhabdomyomas (39%). Eighteen distinct variants were identified (16 in TSC2, 2 in TSC1), including nine novel variants. These comprised nine deletions/insertions, five splice-site, three nonsense, and one missense variant. Most variants (89%) were "private", each observed in a single family.
conclusionThis study provides the first comprehensive genetic analysis of TSC in Egypt. The findings expand the demographic, phenotypic, and genetic spectrum of TSC in an underrepresented population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.